Simultaneous use of genotypic and phenotypic diagnostic tools for detection of rifampicin (RIF) susceptibility may yield discrepant results.
Objective:
To measure the discordance between the RIF-susceptibility results by Xpert MTB/RIF and Mycobacterium Growth Indicator Tube (MGIT), to evaluate if application of both tests to the same sample affects the discrepancy, and to evaluate treatment outcome in patients with the discordant strains.
Design:
Sputa from patients with tuberculosis managed in the penitentiary system of Azerbaijan during 2011–2015 were examined for RIF susceptibility using Xpert MTB/RIF and MGIT. Strains with discrepant results were sequenced.
Results:
Of 532 patients included, 6.2% had discordant RIF-susceptibility results. No significant association of the discordant RIF-susceptibility results with application of both tests on one sample versus sequential samples was found. L511P mutation accounted significantly (p = 0.006) for the discrepancy among those RIF resistant on Xpert MTB/RIF, but sensitive on MGIT. No significant association was identified between the outcomes of treatment with the first- or second-line drugs and the presence of any mutation.
Conclusion:
The Xpert MTB/RIF and MGIT testing may be used in sequential sputum samples without increase in the RIF-susceptibility discordance rate. L511P mutation significantly accounts for discordant RIF-susceptibility results, but its clinical relevance may be low.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. 2016. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva, Switzerland.
2.
AlikhanovaN., AkhundovaI., SeyfaddinovaM., MammadbayovE., MirtskulavaV., Rusch-GerdesS., BayramovR., SuleymanovaJ., KremerK., DaduA., AcostaC.D., HarriesA.D., and DaraM.. 2014. First national survey of anti-tuberculosis drug resistance in Azerbaijan and risk factors analysis. Public Health Action, 4:S17–S23.
3.
European Centre for Disease Prevention and Control. 2016. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe, 2016.
4.
AertsA., HauerB., WanlinM., and VeenJ.. 2006. Tuberculosis and tuberculosis control in European prisons. Int. J. Tuberc. Lung Dis., 10:1215–1223.
5.
PortaelsF., RigoutsL., and BastianI.. 1999. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int. J. Tuberc. Lung Dis., 3:582–588.
6.
GurbanovaE., MehdiyevR., BlondalK., and AltrajaA.. 2015. Predictors of cure in rifampicin-resistant tuberculosis in prison settings with low loss to follow-up. Int. J. Tuberc. Lung Dis., 20:645–651.
7.
AhujaS.D., AshkinD., AvendanoM., BanerjeeR., BauerM., BayonaJ.N., BecerraM. C., BenedettiA., BurgosM., CentisR., ChanE. D., ChiangC.Y., CoxH., D'AmbrosioL., DeRiemerK., Huy DungN., EnarsonD., FalzonD., FlanaganK., FloodJ., Garcia-GarciaM.L., GandhiN., GranichR.M., Hollm-DelgadoM.G., HoltzT.H., IsemanM.D., JarlsbergL.G., KeshavjeeS., KimH.R., KohW.J., LancasterJ., LangeC., de LangeW.C.M., LeimaneV., LeungC.C., LiJ., MenziesD., MiglioriG.B., MishustinS.P., MitnickC.D., NaritaM., O'RiordanP., PaiM., PalmeroD., ParkS., PasvolG., PeñaJ., Pérez-GuzmánC., QuelapioM.I.D., Ponce-de-LeonA., RiekstinaV., RobertJ., RoyceS., SchaafH. S., SeungK.J., ShahL., ShimT.S., ShinS.S., ShiraishiY., Sifuentes-OsornioJ., SotgiuG., StrandM.J., TabarsiP., TupasiT.E., van AltenaR., Van der WaltM., Van der WerfT.S., VargasM.H., ViikleppP., WestenhouseJ., YewW.W., and YimJ.J.. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med., 9:e1001300.
8.
World Health Organization. 2013. Systematic screening for active tuberculosis: principles and recommendations. WHO/HTM/TB/2013.04. Geneva, Switzerland.
9.
World Health Organization. 2013. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva, Switzerland.
10.
KontosF., ManiatiM., CostopoulosC., GittiZ., NicolaouS., PetinakiE., AnagnostouS., TselentisI., and ManiatisA.N.. 2004. Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. J. Microbiol. Methods, 56:291–294.
11.
World Health Organization. 2015. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland.
12.
BoehmeC.C., NabetaP., HillemannD., NicolM.P., ShenaiS., KrappF., AllenJ., TahirliR., BlakemoreR., RustomjeeR., MilovicA., JonesM., O'BrienS.M., PersingD.H., Ruesch-GerdesS., GotuzzoE., RodriguesC., AllandD., and PerkinsM.D.. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med., 363:1005–1015.
13.
SharmaS.K., KohliM., YadavR.N., ChaubeyJ., BhasinD., SreenivasV., SharmaR., and SinghB.K.. 2015. Evaluating the diagnostic accuracy of Xpert MTB/RIF assay in pulmonary tuberculosis. PLoS One, 10:e0141011.
14.
Main Medical Department of the Ministry of Justice of Azerbaijan. 2013. Manual on Tuberculosis Control in the Penitentiary System of Azerbaijan. Baku, Azerbaijan.
15.
World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases. 2009. Good clinical laboratory practice (GCLP).
16.
World Health Organization. 2015. Implementing tuberculosis diagnostics. Policy framework. WHO/HTM/TB/2015.11. Geneva, Switzerland.
17.
ReiderH.L., ChondeT.M., MykingH., UrbanczikR., LaszloA., KimS.J., Van DeunA., and TrébucqA.. 1998. The Public Health Service. National Tuberculosis Reference Laboratory and the National Laboratory Network. Minimum Requirements, Role and Operation in a Low-Income Country. International Union Against Tuberculosis and Lung Disease, Paris, France.
18.
KentP.T., and KubicaG.P.. 1985. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta.
19.
SiddiqiS.H., and Ruesch-GerdesS.. 2006. MGIT procedure manual for BACTEC MGIT 960 TB system. Foundation for Innovative New Diagnostics.
20.
TelentiA., HonoreN., BernasconiC., MarchJ., OrtegaA., HeymB., TakiffH.E., and ColeetS.T.. 1997. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol., 35:719–723.
21.
SITVITWEB—A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Available at www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE
22.
KamerbeekJ., SchoulsL., KolkA., van AgterveldM., van SoolingenD., KuijperS., BunschotenA., MolhuizenH., ShawR., GoyalM., and van EmbdenJ.. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol., 35:907–914.
23.
TB CARE I. 2014. International Standards for Tuberculosis Care, Edition 3. TB CARE I., The Hague.
24.
Van DeunA., AungK.J., BolaV., LebekeR., HossainM.A., de RijkW.B., RigoutsL., GumusbogaA., TorreaG., and B.C, and de Jong. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J. Clin. Microbiol., 51:2633–2640.
25.
Van DeunA., BarreraL., BastianI., FattoriniL., HoffmannH., KamK.M., RigoutsL., Rüsch-GerdesS., and WrightA.. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol., 47:3501–3506.
26.
BottgerE.C.2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect., 17:1128–1134.
27.
DominguezJ., BoettgerE.C., CirilloD., CobelensF., EisenachK.D., GagneuxS., HillemannD., HorsburghR., Molina-MoyaB., NiemannS., TortoliE., WhitelawA., and LangeC.. 2016. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int. J. Tuberc. Lung Dis., 20:24–42.
28.
JamiesonF.B., GuthrieJ.L., NeemuchwalaA., LastovetskaO., MelanoR.G., and MehaffyC.. 2014. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J. Clin. Microbiol., 52:2157–2162.
29.
OcheretinaO., EscuyerV.E., MabouM.M., Royal-MardiG., CollinsS., VilbrunS.C., PapeJ.W., and FitzgeraldD.W.. 2014. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One, 9:e90569.
30.
RigoutsL., GumusbogaM., de RijkW.B., NduwamahoroE., UwizeyeC., de JongB., and Van DeunA.. 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J. Clin. Microbiol., 51:2641–2645.
31.
RamaswamyS., and MusserJ.M.. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis., 79:3–29.
32.
SchonT., JureenP., ChryssanthouE., GiskeC.G., KahlmeterG., HoffnerS., and AngebyK.. 2013. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J. Antimicrob. Chemother., 68:2074–2077.
33.
YangB., KogaH., OhnoH., OgawaK., FukudaM., HirakataY., MaesakiS., TomonoK., TashiroT., and KohnoS.. 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother., 42:621–628.
34.
BalganeshM., KuruppathS., MarcelN., SharmaS., NairA., and SharmaU.. 2010. Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob. Agents Chemother., 54:5167–5172.
35.
Ramon-GarciaS., MartinC., ThompsonC.J., and AinsaJ.A.. 2009. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob. Agents Chemother., 53:3675–3682.
SteingartK.R., SchillerI., HorneD.J., PaiM., BoehmeC.C., and DendukuriN.. 2014. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst. Rev.CD009593.
38.
BradenC.R., MorlockG.P., WoodleyC.L., JohnsonK.R., ColombelA.C., CaveM.D., YangZ., ValwayS.E., OnoratoI.M., and CrawfordJ.T.. 2001. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin. Infect. Dis., 33:e42–e47.
39.
ShamputaI.C., JugheliL., SadradzeN., WilleryE., PortaelsF., SupplyP., and RigoutsL.. 2006. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir. Res., 7:99.
40.
European Society of Clinical Microbiology and Infectious Diseases. European Committee on Antimicrobial Susceptibility Testing. Available at www.eucast.org
41.
Clinical and Laboratory Standards Institute. 2015. M100-S25 performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement.
